The effect of the Cl− channel blockers niflumic acid (NFA), 5‐nitro‐2‐(3‐phenylpropylamino)‐benzoic acid (NPPB), 4,4′‐diisothiocyanatostilbene‐2,2′‐disulfonic acid (DIDS), and anthracene‐9‐carboxylic acid (A‐9‐C), on Ca2+ signalling in rat pulmonary artery smooth muscle cells was examined. Intracellular Ca2+ concentration ([Ca2+]i) was monitored with either fura‐2 or fluo‐4, and caffeine was used to activate the ryanodine receptor, thereby releasing Ca2+ from the sarcoplasmic reticulum (SR).

NFA and NPPB significantly increased basal [Ca2+]i and attenuated the caffeine‐induced increase in [Ca2+]i. These Cl− channel blockers also increased the half‐time (t1/2) to peak for the caffeine‐induced [Ca2+]i transient, and slowed the removal of Ca2+ from the cytosol following application of caffeine. Since DIDS and A‐9‐C were found to adversely affect fura‐2 fluorescence, fluo‐4 was used to monitor intracellular Ca2+ in studies involving these Cl− channel blockers. Both DIDS and A‐9‐C increased basal fluo‐4 fluorescence, indicating an increase in intracellular Ca2+, and while DIDS had no significant effect on the t1/2 to peak for the caffeine‐induced Ca2+ transient, it was significantly increased by A‐9‐C.

In the absence of extracellular Ca2+, NFA significantly increased basal [Ca2+]i, suggesting that the release of Ca2+ from an intracellular store was responsible for the observed effect.

Depleting the SR with the combination of caffeine and cyclopiazonic acid prevented the increase in basal [Ca2+]i induced by NFA. Additionally, incubating the cells with ryanodine also prevented the increase in basal [Ca2+]i induced by NFA.

These data show that Cl− channel blockers have marked effects on Ca2+ signalling in pulmonary artery smooth muscle cells. Furthermore, examination of the NFA‐induced increase in [Ca2+]i indicates that it is likely due to Ca2+ release from an intracellular store, most probably the SR.

British Journal of Pharmacology (2003) 140, 1442–1450. doi:10.1038/sj.bjp.0705571

2003-01-01·British Journal of Pharmacology

Anomalous effect of anthracene‐9‐carboxylic acid on calcium‐activated chloride currents in rabbit pulmonary artery smooth muscle cells

Article

作者: Iain A Greenwood ; Angela S Piper

Ca2+‐activated Cl− currents (ICl(Ca)) evoked by K+‐free pipette solutions containing 500 nM Ca2+ were recorded in rabbit pulmonary artery smooth muscle cells. A voltage step protocol in which the cells were stepped to +70 mV and then to −80 mV produced outward and inward Cl− currents respectively that exhibited distinctive voltage‐ and time‐dependent kinetics that remained consistent for the recording period.

Application of the Cl− channel inhibitor anthracene‐9‐carboxylic acid (A‐9‐C, 500 μM), produced a small inhibition of the maximum outward Cl− current at +70 mV (21±10%) but augmented the amplitude of the instantaneous inward relaxation at −80 mV by 321±34% (n=12).

The current recorded in the absence and presence of A‐9‐C reversed at the theoretical Cl− equilibrium potential and the reversal potential was shifted by about −40 mV upon replacement of external chloride ion by the more permeant anion thiocyanate. Currents in the absence and presence of A‐9‐C were similarly affected by 100 μM niflumic acid.

Augmentation of the inward current at −80 mV by A‐9‐C required prior depolarization, i.e. A‐9‐C did not simply activate a Cl− current at negative membrane potentials. Moreover the degree of augmentation was independent of the internal Ca2+ for concentrations between 100 nM and 1 μM Ca2+.

The data from the present study confirm previous observations that the inhibitory effect of Cl− channel blockers is modified when [Ca2+]i is maintained at higher than normal resting concentrations.

British Journal of Pharmacology (2003) 138, 31–38. doi:10.1038/sj.bjp.0705000

2001-05-15·Alimentary Pharmacology & Therapeutics1区 · 医学

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

1区 · 医学

Article

作者: J. B. M. J. Jansen ; A. H. A. M. Van Oijen ; M. J. R. Janssen ; A. L. M. Verbeek ; W. A. De Boer

Background:Triple therapies with proton pump inhibitor/ranitidine bismuth citrate (RBC), clarithromycin (C) and either amoxicillin (A) or a nitroimidazole (I) are widely accepted as treatment for Helicobacter pylori infection. However, it is not clear which of these antibiotic combinations should be preferred.Aim:To evaluate whether there is a difference in efficacy between triple therapies with proton pump inhibitor/RBC, clarithromycin and either amoxicillin or a nitroimidazole.Methods:The literature was examined for randomized trials comparing proton pump inhibitor/RBC‐C‐A and proton pump inhibitor/RBC‐C‐I. Studies were grouped according to the type of acid inhibitor used (proton pump inhibitor or RBC) and differences between pooled cure rates were calculated.Results:Forty‐seven studies were identified: seven using RBC, 39 using proton pump inhibitor, one using both. RBC‐C‐I was somewhat superior to RBC‐C‐A, although this difference only reached statistical significance in intention‐to‐treat analysis. Overall, proton pump inhibitor‐C‐I and proton pump inhibitor‐C‐A were equally effective, but in nitroimidazole‐susceptible strains, proton pump inhibitor‐C‐I performed better, in nitroimidazole‐resistant strains, proton pump inhibitor‐C‐A performed better. No serious side‐effects were reported and pooled drop‐out rates were equal.Conclusions:In general, proton pump inhibitor‐C‐I and proton pump inhibitor‐C‐A are equally effective and therefore other factors such as local prevalence of resistant strains, cost of therapy and options for second‐line treatment should determine which regimen should be preferred. When using RBC, the RBC‐C‐I combination is somewhat superior to RBC‐C‐A.

项与 A群C群脑膜炎球菌多糖疫苗 (浙江天元生物) 相关的新闻（医药）

2024-12-19

·摩熵医药

国产疫苗价格战白热化！“亿级”品种步长制药投入千万，抢滩国内市场……

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 12月18日，山东步长制药发布公告，其控股子公司浙江天元生物药业的“水痘减毒活疫苗”药品注册临床试验申请获国家药品监督管理局的受理。截至2024年11月底，公司已为该疫苗项目投入约2,693.65万元的研发资金。截图来源：企业公告疫苗市场竞争格局激烈，国外头部药企占据主导地位水痘减毒活疫苗，适应症为：接种本疫苗后，可刺激机体产生抗水痘-带状疱疹病毒的免疫力。用于预防水痘。据摩熵医药数据库显示，水痘减毒活疫苗在2023年全国院内市场的销售额超1亿元，同比增长达15.01%。截图来源：摩熵医药（原药融云）全国医院销售数据库从2023年全国院内水痘减毒活疫苗销售TOP 10榜单的企业竞争格局来看，葛兰素史克以高达51.51%的市场份额，强势占据院内市场领先地位；长春百克生物科技紧随其后，凭借23.96%的市场份额位列第二；而长春祈健生物制品则以9.37%的市场份额，稳固占据榜单第三名的席位。截图来源：摩熵医药（原药融云）全国医院销售数据库目前，国内已上市水痘减毒活疫苗的药企有8家，包括北京生物制品研究所、北京民海生物、科兴（大连）疫苗技术、上海荣盛生物药业、成都生物制品研究所、长春百克生物、上海生物制品、长春祈健生物制品药企，市场竞争异常激烈。截图来源：摩熵医药（原药融云）中国药品批文数据库价格战内卷愈演愈烈，国产疫苗行业深陷困境当前，国产疫苗行业正面临严峻的价格战挑战。各大头部疫苗企业纷纷加入降价行列，价格战波及范围不断扩大，从流感疫苗、HPV疫苗到狂犬疫苗、肺炎疫苗等多个品类均受到波及。 2024国内部分疫苗降价情况 2024年上半年，流感疫苗市场的价格战尤为激烈，四价流感疫苗成为价格战的主战场，平均降幅超过30%，价格甚至跌破百元大关。国药集团、华兰疫苗、北京科兴及金迪克等企业均深陷其中，而华兰疫苗在疫苗批签发量上持续领跑国内。此外，国光生物和江苏中慧元通也推出了四价流感疫苗，进一步加剧了市场竞争。此外，天津市近期发布的非免疫规划疫苗集中挂网采购项目价格调整公告也显示，多家生物制品研究所下调了水痘减毒活疫苗等多种疫苗的价格，国产疫苗行业的价格战压力进一步加剧。国产疫苗企业寻求新突破，聚焦新产品和出海战略面对如此激烈的行业竞争和不断下滑的销售业绩，国内疫苗企业纷纷调整战略，寻求新的业绩突破口。步长制药此次受理的水痘减毒活疫苗正是其在新产品研发方面的重要布局之一。截图来源：摩熵医药（原药融云）中国药品审评数据库目前，步长制药在疫苗领域已拥有4项产品，并有5项产品正在研发中，涵盖了流感病毒裂解疫苗（成人及儿童型）、A群C群脑膜炎球菌多糖疫苗、ACYW135群脑膜炎球菌多糖疫苗、四价流感病毒裂解疫苗(鸡胚、成人型)、四价流感病毒裂解疫苗(MDCK细胞)、水痘减毒活疫苗、带状疱疹减毒活疫苗等。其中流感病毒裂解疫苗相关剂型在2023年全国院内市场的销售额超1亿元。截图来源：摩熵医药（原药融云）全国医院销售数据库国产疫苗行业正处于前所未有的挑战与机遇并存的关键时期。在价格战白热化的背景下，国产疫苗企业需要不断创新和突破，以新产品研发和出海战略为引领，推动行业实现高质量发展。未来，国内疫苗企业的战略将主要聚焦在开发新产品和拓展海外市场两大方向，以寻求新的增长点和发展机遇。结语步长制药的“水痘减毒活疫苗”受理，无疑为国产水痘疫苗市场增添了新的变数。随着更多国产疫苗企业的加入和创新产品的推出，国产疫苗行业有望迎来更加广阔的发展前景。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

疫苗医药出海

100 项与 A群C群脑膜炎球菌多糖疫苗 (浙江天元生物) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07AH03	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脑膜炎	中国	浙江天元生物药业有限公司	2007-09-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2008	N/A	乳腺癌新辅助	52	TAC	窪鏇夢齋窪淵構鹹艱夢(鏇襯襯鏇願餘鑰憲窪壓) = 鏇夢鹹衊憲鑰糧網壓齋築製襯襯憲範膚築遞鏇 (齋觸壓簾網鬱艱醖築顧 ) 更多	-	2008-05-20
				A and C	窪鏇夢齋窪淵構鹹艱夢(鏇襯襯鏇願餘鑰憲窪壓) = 築觸鹹襯鬱齋遞壓醖製築製襯襯憲範膚築遞鏇 (齋觸壓簾網鬱艱醖築顧 ) 更多